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Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic arthropathy of childhood which is
believed to be influenced by both genetic and environmental factors. The progress in identifying
genes underlying JIA susceptibility using candidate gene association studies has been slow. Several
associations between JIA and variants in the genes encoding the human leukocyte antigens (HLA)
have been confirmed and replicated in independent cohorts. However it is clear that genetic
variants outside the HLA also influence susceptibility to JIA. While a large number of non-HLA
candidate genes have been tested for associations, only a handful of reported associations such as
PTPN22 have been validated. In this review we discuss the principles behind genetic studies of
complex traits like JIA, and comprehensively catalogue non-HLA candidate-gene association studies
performed in JIA to date and review several validated associations. Most candidate gene studies are
underpowered and do not detect associations, and those that do are often not replicated. We also
discuss the principles behind genome-wide association studies and discuss possible implications for
identifying genes underlying JIA. Finally we discuss several genetic variants underlying multiple
clinically distinct autoimmune phenotypes.
Juvenile idiopathic arthritis rers to a group of chronic
arthropathies of childhood[1]. According to the Interna-
tional League of Associations for Rheumatology criteria,
JIA comprises seven subtypes[2]. These include systemic
JIA (sJIA), oligoarticular JIA, rheumatoid factor (RF)-neg-
ative polyarticular JIA, RF-positive polyarticular JIA,
enthesitis related arthritis (ERA), psoriatic arthritis and
undifferentiated JIA. The relatively homogeneous sub-
types of JIA share clinical features with other chronic
autoimmune disorders such as rheumatoid arthritis (RA),
psoriasis or spondyloarthropathies [3]. Autoimmune dis-
orders are relatively common in the population, esti-
mated to have a prevalence of about ~5% in the US. While
clinical and laboratory features distinguish many of these
autoimmune disorders, there is accumulating evidence to
support the hypothesis that clinically distinct autoim-
mune phenotypes share common genetic susceptibility
factors. In this review, we will examine the genetic factors
that underlie JIA susceptibility, and discuss some of the
genetic factors that underlie multiple autoimmune phe-
notypes.
JIA is an autoimmune disorder
All subtypes of JIA are characterized by persistent joint
swelling caused by an accumulation of synovial fluid and
thickening of the synovial lining. There is evidence to sup-
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port the involvement of different components of the
immune system in the etiopathogenesis of JIA. The syno-
vial tissue contains various inflammatory cells including
neutrophils, plasma cells, dendritic cells and a high pro-
portion of activated T-cells [4-6]. The recruitment of pro-
inflammatory cells into the synovium of a child with JIA
is believed to be mediated by chemokines that selectively
attract Th1 T-cells [7-9]. These T-cells are characterized by
the production of interleukin (IL)-2, interferon-γ, and
tumor necrosis factor (TNF)-β. Many other autoimmune
disorders including RA, inflammatory bowel disease
(IBD), psoriasis, and type 1 diabetes mellitus (T1DM) are
also associated with Th1-dominant responses[10,11].
Several studies have demonstrated that Th1 cytokines also
predominate in the synovial tissue and synovial fluid
samples from children with JIA [12-15]. Pro-inflamma-
tory cytokines including sCD154 are significantly elevated
in sera of children with JIA as well [16]. Thus, there is
compelling evidence that activated T-lymphocytes play a
role in the pathogenesis of JIA.
Involvement of the other components of the immune sys-
tem is also evident in JIA. For instance a significant pro-
portion of children with JIA have antinuclear antibodies,
and some children have rheumatoid factors, suggesting a
role of the humoral component of the immune system.
The predominance of neutrophils in the synovial fluid of
children with JIA, elevated levels of monocyte derived
inflammatory cytokines, and complement activation have
led to investigations of the involvement of innate
immune system in JIA. Using gene expression analysis,
Jarvis et al have found that neutrophils in children with
polyarticular JIA show differences in levels of expression
of over 700 genes compared to healthy controls [17].
These differences persisted despite clinical responses to
pharmacological therapy, suggesting that neutrophils
might be intrinsically involved in the pathogenesis of pol-
yarticular subtypes of JIA. Together, these data point to the
role of aberrant immune/inflammatory responses in JIA.
Evidence that genetic factors underlie JIA 
susceptibility
Twin and family studies have provided evidence for
genetic contributions to susceptibility of JIA. Twin studies
have shown that the monozygotic twin concordance rates
for JIA range between 25 to 40 %, a risk that is substan-
tially greater than the population prevalence of 1 in 1000
[18]. An analysis of twin pairs in a national JIA registry
showed that at least 80 % of the twin pairs in the registry
were monozygotic, when one would expect only a third to
be monozygotic [19]. Similarly examination of affected
sibling pairs with JIA reveals concordance for disease
onset, and disease course[20,21]. Furthermore siblings
were more likely to develop JIA at the same age of onset,
rather than the same calendar year. The prevalence of JIA
among siblings of probands is about 15–30 times that of
the general population prevalence[22,23]. Finally a com-
puterized probabilistic record-linking analysis identified
several clusters of children with JIA sharing common
ancestors [23]. Together these studies provide compelling
evidence for a substantial genetic component underlying
JIA susceptibility.
JIA is a complex genetic trait
Complex genetic traits are those phenotypes that do not
exhibit classic Mendelian inheritance patterns which
could be attributed to variants in a single gene
locus[24,25]. Complex traits are often believed to be
determined by a number of genetic and environmental
factors. While increased prevalence of JIA has been shown
in twins or siblings of probands with JIA, parent-offspring
pairs and extended multiplex JIA families are relatively
uncommon in JIA. Relatives of JIA probands have
increased prevalence of other autoimmune disorders
[26,27]. The best characterized genetic factors, i.e., poly-
morphisms in the genes encoding human leukocyte anti-
gen (HLA -DR) have been estimated to account for only
17 % of the proportion of sibling recurrence risk in
JIA[28]. These factors support the notion that JIA is a com-
plex phenotype[22].
Exploring the genetic basis of disease
Linkage and association studies are analytical approaches
used to dissect the genetic basis of common diseases. Both
studies rely on the same principles and assumptions,
namely the co-inheritance of polymorphisms linked to a
disease allele [29,30]. Linkage studies test whether a phe-
notype and a marker allele show correlated transmission
within a pedigree[24]. Linkage analysis requires large col-
lections of multiplex families, in which multiple family
members have the phenotype of interest. Association
studies test whether a phenotype and a marker allele show
correlated occurrence in a population[24]. Association
studies compare unrelated affected and unaffected indi-
viduals within a population. An allele at a locus of interest
is associated with a phenotype if it occurs at a significantly
higher (or lower) frequency among cases compared to
controls. The selection of controls is very critical in case-
control association studies, since results can be affected by
population stratification. Family-based association stud-
ies, including the transmission disequilibrium test (TDT)
are not affected by population stratification, since they use
untransmitted alleles as controls within families. When
linkage or association between a marker and a disease is
detected, it implies either that the marker is the disease
allele, or that the marker is in linkage disequilibrium (LD)
with the disease allele. LD is a non-random association of
alleles at two or more loci and is a measure of co-segrega-
tion of alleles in a population[31,32].Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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The search for genetic factors underlying susceptibility to
complex traits can be classified as functional candidate
gene studies or genome-wide studies. Functional candi-
date-gene studies begin by selecting genes whose known
functions suggest that they could be influencing the phe-
notype of interest. In genome-wide studies, the genome is
searched for susceptibility loci, and no assumptions are
made about the candidacy of particular genes or genomic
regions. Until now most association studies could exam-
ine only a small fraction of the sequence variation in an
affected individual. However, advances in genome tech-
nologies, and the availability of haplotype and LD infor-
mation from the HapMap project now facilitate
comprehensive genome-wide searches for genetic influ-
ences [29].
Genes underlying JIA susceptibility
Genetic variants underlying JIA susceptibility have been
reviewed extensively[18,33-37]. The major histocompati-
bility complex (MHC) region on chromosome 6 is packed
with over 200 genes, many of which are essential to the
immune system. Numerous associations between HLA
polymorphisms and JIA subtypes have been reported in
multiple populations (Table 1). Within the HLA complex
there are genes encoding class I (HLA A, B and C), and
class II (HLA-DR, DP and DQ) molecules. The class I allele
HLA-A2 is associated with different JIA subtypes, espe-
cially in those with early onset[38,39]. HLA-B27 is associ-
ated with enthesitis related JIA [39-41]. Oligoarticular JIA
is the subtype with the most HLA class II associations. Oli-
goarticular JIA is positively associated with HLA
DRB1*01, DRB1*08, DRB1*11, DRB1*13, DPB1*02 and
DQB1*04[38,39,41-44]. HLA DRB1*04 and DRB1*07 are
seen less frequently in children with oligoarticular JIA
than controls, suggesting that they are protec-
tive[38,39,41,44]. Polyarticular RF negative JIA is associ-
ated with DRB1*08 and DPB1*03 [41,44]. Polyarticular
RF-positive JIA, which is phenotypically similar to adult
RA, is associated with DRB1*04, DQA1*03, and
DQB1*03[41,44]. Psoriatic arthritis was found in the
study by Thomson et al to be associated with HLA
DRB1*01, and DQA1*0101[41]. Associations between
sJIA and HLA DRB1*04 have also been reported[45,46]. A
recent study reported an association between a polymor-
phism in the HLA-G region and JIA, with a pronounced
association in female subjects [47]. While some associa-
tions appear to be secondary to LD (for instance HLA DR
and DQ alleles), most associations are not explained by
LD, suggesting that several HLA loci independently con-
tribute to susceptibility of JIA or its subtypes. A study
involving over 600 children with JIA and 254 ethnicity-
matched healthy controls confirmed several previously
reported HLA associations, and also identified age-specific
windows of susceptibility for the different HLA alle-
les[39]. This study also demonstrated that the number of
susceptibility alleles was inversely proportional to the age
of onset of JIA. Among children who carried HLA-A2,
DPB1*0201, and one susceptible -DR allele the median
age of onset of oligoarticular JIA was just 2.4 years.
Non HLA Associations
A number of non-HLA genes have been tested for associa-
tion with JIA. Only a few of these have been replicated in
additional cohorts. Some of these are reviewed by Phelan
et al [33]. A systematic review of the literature suggests
that about 100 different non-HLA candidate loci have
been investigated for associations with JIA, in over 150
tests for genetic association in different cohorts (Table 2).
Although ~25 % of all tests reported finding an associa-
tion, independent confirmations are found for only a
handful of candidate genes including PTPN22, MIF,
SLC11A6, WISP3, and TNFA (Table 3). Many studies ana-
lyze JIA as a single phenotype. While combining clinically
distinct entities such as systemic JIA and oligoarticular JIA
might confound the results, stratification of subjects leads
to further loss of power. Finally most studies do not cor-
rect for multiple comparisons, which might result in false
positive associations that cannot be ultimately confirmed.
The ranges of cases in these studies varied from 33 indi-
viduals to 950 individuals with JIA, and the number of
controls ranged from 40 to 1952. The median number of
cases was 130, while the median number of controls was
276. Only a few studies used more than 800 cases of JIA.
These observations suggest that most of these studies are
underpowered to detect associations with modest odds
ratios (OR) (Table 4). Results of studies in other complex
genetic traits suggest that most associated variants have
only a modest OR of about 1.5. These observations rein-
force the importance of properly performed and reported
studies including the capacity to replicate.
Table 1: Associations between JIA subtypes and different HLA alleles.
Phenotype Alleles conferring susceptibility Protective alleles
Oligoarticular A2, DRB1*01, DRB1*08, DRB1*11, DRB1*13, DPB1*02, DQA1*04, DQB1*04 DRB1*04, DRB1*07, DQA1*03
Polyarticular RF+ DRB1*04, DQA1*03, DQB1*03 DQA1*02
Polyarticular RF- A2, DRB1*08, DQA1*04, DPB1*03
Psoriatic DRB1*01, DQA1*0101 DRB1*04, DQA1*03
ERA B27, DRB1*01, DQA1*0101, DQB1*05
Systemic DRB1*04, DRB1*11, DQA1*05Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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Table 2: Non-HLA candidate markers tested for association with JIA.
Marker ASSN Cases Controls Design NOTES Author ID
ACE Y 82 48 CC Insertion/deletion polymorphism Alsaid [119]
ADAM33 N 86 270 CC Schubert [120]
ADRB2 N 86 270 CC Schubert [120]
ADRB2 N 348 448 CC Pont-Kingdon [121]
Alpha 1 AT Y 96 4565 CC Arnaud [122]
BV13S2 N 120 500 CC Epplen [56]
BV62& N 120 500 CC Epplen [56]
BV6S3 N 120 500 CC Epplen [56]
CARD15 N 86 270 CC Schubert [120]
CBG N 463 276 CC Donn [123]
CCR3 N 86 270 CC Schubert [120]
CCR5 N 86 270 CC Schubert [120]
CCR5 Y 819 TDT Protective Prahalad [79]
CCR5 N 524 658 CC Lindner [80]
CCR5 Y 101 104 CC Positive association in systemic+poly Scheibel [124]
CD3D N 120 500 CC Epplen [56]
CD40L N 120 500 CC Epplen [56]
CRH N 463 276 CC Donn [123]
CSF2 N 86 270 CC Schubert [120]
CTLA4 Y 197 362 CC Miterski [59]
CTLA4 N 72 475 CC Suppiah [125]
CTLA4 N 86 270 CC Schubert [120]
CTLA4 N 818 518 CC Prahalad [113]
CTSL2 N 530 559 CC Viken 2007 [126]
CYP19 N 463 276 CC Donn [123]
D17S795 N 173 416 CC Miterski [59]
D17S807 N 172 412 CC Miterski [59]
D17S821 N 173 412 CC Miterski [59]
DDR1 N 135 199 TDT Zeggini [127]
ESR1 N 463 276 CC Donn [123]
FAS N 342 255 CC Donn [128]
FCER1B N 86 270 CC Schubert [120]
FCRL3 Y 524 1030 CC Association seen in poly JIA subset Eike [129]
FGFA N 120 500 CC Epplen [56]
FOXp3 N 761 402 CC Eastell [130]
GSTM1 N 103 90 CC Rohr [131]
GSTP1 N 103 90 CC Rohr [131]
GSTT1 Y 103 90 CC Rohr [131]
GZMB N 133 384 CC Only systemic JIA studied Donn [95]
IFNA N 120 500 CC Epplen [56]
IFNA1 N 417 276 CC Donn [69]
IFNG N 417 276 CC Donn [69]
IFNG N 165 395 CC Miterski [59]
IFNG N 130 103 CC Cinek [132]
IgA def Y 1673 CC Data derived from several studies. Cassidy [133]
IKBL N 170 389 CC Miterski [59]
IL1 cluster Y 235 335 CC Only systemic JIA studied. Two stage study Stock [71]
IL1R cluster Y 235 335 CC Only systemic JIA studied. Two stage study Stock [71]
IL1A N 417 276 CC Donn [69]
IL1A Y 269 99 CC Association with early onset oligo JIA McDowell [68]
IL1A N 130 103 CC Cinek [132]
IL1A N 120 500 CC Epplen [56]
IL1B Y 107 630 CC Cimaz [134]
IL1B N 130 103 CC Non-significant association reported. Cinek [132]
IL1R N 130 103 CC Cinek [132]
IL1RA N 107 630 CC Cimaz [134]
IL1RN Y 235 306 CC Vencovsky [135]
IL2 N 417 276 CC Donn [69]
IL2 N 86 270 CC Schubert [120]Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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IL2 N 130 103 CC Cinek [132]
IL2 N 120 500 CC Epplen [56]
IL3 N 86 270 CC Schubert [120]
IL4 N 417 276 CC Donn [69]
IL4 N 86 270 CC Schubert [120]
IL4 N 72 165 CC Trend in female cases Suppiah [136]
IL4 Y 130 103 CC Cinek [132]
IL4R N 72 165 CC Trend in female cases Suppiah [136]
IL4RA N 130 103 CC Cinek [132]
IL5RA N 120 500 CC Epplen [56]
IL6 N 417 276 CC Donn [69]
IL6 Y 222 TDT Only systemic JIA patients studied Ogilvie [76]
IL6 N 86 270 CC Schubert [120]
IL6 N 130 103 CC Cinek [132]
IL8 N 86 270 CC Schubert [120]
IL10 N 417 276 CC Donn [69]
IL10 N 86 270 CC Schubert [120]
IL10 Y 172 473 CC Only systemic JIA patients studied Fife [137]
IL10 N 130 103 CC Cinek [132]
IL12 N 130 103 CC Cinek [132]
IL13 N 86 270 CC Schubert [120]
IL15 Y 107 270 CC Bierbaum [138]
IL18 N 86 270 CC Schubert [120]
IL18 Y 33 176 CC sugiura [139]
IL1A N 417 276 CC Donn [69]
IL1A Y 269 99 CC Association with early onset oligo JIA McDowell [68]
IL1A N 130 103 CC Cinek [132]
IL1A N 120 500 CC Epplen [56]
IL1B Y 107 630 CC Cimaz [134]
IL1B N 130 103 CC Non-significant association reported. Cinek [132]
IL1R N 130 103 CC Cinek [132]
IL1RA N 107 630 CC Cimaz [134]
IL1RN Y 235 306 CC Vencovsky [135]
IL2 N 417 276 CC Donn [69]
IL2 N 86 270 CC Schubert [120]
IL2 N 130 103 CC Cinek [132]
IL2 N 120 500 CC Epplen [56]
IL3 N 86 270 CC Schubert [120]
IL4 N 417 276 CC Donn [69]
IL4 N 86 270 CC Schubert [120]
IL4 N 72 165 CC Trend in female cases Suppiah [136]
IL4 Y 130 103 CC Cinek [132]
IL4R N 72 165 CC Trend in female cases Suppiah [136]
IL4RA N 130 103 CC Cinek [132]
IL5RA N 120 500 CC Epplen [56]
IL6 N 417 276 CC Donn [69]
IL6 Y 222 TDT Only systemic JIA patients studied Ogilvie [76]
IL6 N 86 270 CC Schubert [120]
IL6 N 130 103 CC Cinek [132]
IL8 N 86 270 CC Schubert [120]
IRF1 Y 417 276 CC Donn [69]
IRF1 N 765 508 CC Fife [140]
IRF2 N 120 500 CC Epplen [56]
LMP 7 Y 207 50 CC Prahalad [141]
MBL N 93 48 CC Kang [142]
MCP1 N 86 270 CC Schubert [120]
MCP1 N 66 150 CC Ozyurek [143]
MEFV Y 71 100 CC Included 12 subjects with vasculitis Ozen [144]
MEFV Y 950 728 CC Association in psoriatic JIA after correction for multiple testing Day [145]
MHC2TA Y 74 316 CC O'Doherty [146]
MICA Y 128 113 CC Association with A4 allele Nikitina Zake [147]
MIF Y 526 259 CC Donn [60]
MIF N 150 390 CC Miterski [59]
Table 2: Non-HLA candidate markers tested for association with JIA. (Continued)Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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MIF Y 224 341 CC Association with allele 05 Miterski [59]
MIF Y 321 TDT Donn [61]
MIF N 86 270 CC Schubert [120]
MIF N 67 153 CC Berdeli [62]
MTHFR N 56 62 CC Huemer [148]
MTR N 56 62 CC Huemer [148]
MTRR N 56 62 CC Huemer [148]
NLP3 Y 950 728 CC Association in psoriatic JIA after correction for multiple testing Day [145]
NOD2 N 950 728 CC Association in psoriatic JIA before correction for multiple testing Day [145]
NOS33 N 86 270 CC Schubert [120]
Osteopontin N 119 200 CC Oligo JIA only. Marciano [149]
PAFAH N 86 270 CC Schubert [120]
PRF1 N 133 384 CC Only systemic JIA studied Donn [95]
PRL N 463 276 CC Donn [123]
PSTPIP1 N 950 728 CC Association in psoriatic JIA before correction for multiple testing Day [145]
PTPN22 Y 661 595 CC Hinks [84]
PTPN22 N 230 1400 CC Seldin [85]
PTPN22 Y 320 555 CC Viken [86]
PTPN22 Y 130 400 CC Cinek [87]
PTPRC N 161 362 CC Miterski [59]
Rab27a N 133 384 CC Only systemic studied Donn [95]
RANTES N 86 270 CC Schubert [120]
SELP N 86 270 CC Schubert [120]
SH2D2A Y 210 558 CC Smerdel [150]
SLC11A1 Y 119 111 CC Also named NRAMP1 Sanjeevi [66]
SLC11A1 Y 234 639 TDT Runstadler [67]
SLC26A2 Y 826 617 CC Association seen only in systemic jia Lamb [151]
SUMO4 N 668 484 CC Gibbons [152]
TAP Y 285 165 CC Despite correcting for HLA Ploski [153]
Tapasin Y 156 TDT Only systemic studied Bukulmez [154]
TCRBv6.1 Y 126 207 CC Association in HLADQA1*0101 positive subjects Maksymowych [155]
TCRBv6.1 N 77 40 CC only HLADQA1*0101 positive subjects Ploski [156]
TCRBv6.1 N 120 500 CC Epplen [56]
TCRDVAJ N 120 500 CC Epplen [56]
TEA N 120 500 CC Epplen [56]
TGFB1 N 130 103 CC Cinek [132]
TLR4 N 313 TDT Lamb [157]
TLR4 N 86 270 CC Schubert [120]
TLR9 N 86 270 CC Schubert [120]
TNFA Y 128 114 CC Association with A2 allele Nikitina Zake [147]
TNFA Y 142 388 CC Association with allele 6 Miterski [59]
TNFA N 170 415 CC Miterski [59]
TNFA Y 228 196 CC Association in psoriatic, RF-negative subtypes Schmeling [58]
TNFA N 86 270 CC Schubert [120]
TNFA N 55 68 CC Difference between oligo and systemic Modesto [158]
TNFA N 107 630 CC Cimaz [134]
TNFA Y 120 500 CC Microsatellite Epplen [56]
TNFB N 128 114 CC Nikitina Zake [147]
TNFB N 86 270 CC Schubert [120]
TNFR1 N 132 334 CC Miterski [59]
TNFR2 N 435 261 CC Zeggini [159]
TNFR2 N 146 428 CC Miterski [59]
TRAF1 Y 67 1952 CC Subjects genotyped as part of genome-wide association Behrens [160]
UNC13D N 133 384 CC Only systemic JIA studied Donn [95]
WISP3 Y 159 263 CC Lamb [77]
WISP3 Y 181 355 CC Replication study Lamb [77]
Marker: Gene or locus studied for association. Assn: Association; CC: case-control; TDT: transmission-disequilibrium testing.
Table 2: Non-HLA candidate markers tested for association with JIA. (Continued)Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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Interpreting the different associations (or lack of associa-
tions) between genetic variants and phenotypes can be
further complicated by differences in phenotype descrip-
tion. JIA comprises several sub-phenotypes with distinct
clinical features and outcomes[48]. Although the ILAR
classification criteria, which are increasingly being used to
describe juvenile arthritis attempts to define homogenous
subtypes, there are still some challenges. For instance a
child with four affected joints is classified as oligoarticular
JIA, while a child with five affected joints is classified as
polyarticular JIA, although clinically the difference is not
significant. Similarly, a child with five affected joints and
another with over 20 joints are both classified as polyar-
ticular, although clinically they appear distinct. While this
can be addressed in part, by analyzing children with JIA as
a group, and then performing analyses by subtypes, this
results in multiple comparisons. One approach to address
this issue might be to use genetic information to stratify
subjects into subtypes, and this might results in more
homogenous subtypes. For instance studies of adult RA
subjects frequently stratify the subjects based on presence
or absence of the shared HLA-DR epitope[49,50]. Simi-
larly, it might be reasonable to stratify JIA patients by HLA
associations while conducting genetic studies. It also
would better facilitate comparisons of genetic studies per-
formed in different populations. Finally, this would also
help to delineate associations due to LD. For instance the
MHC region has extensive LD, and associations described
with variants in this region could be due to LD with HLA
polymorphisms. Together, these observations reinforce
the need for meticulous attention to defining the pheno-
types and caution with interpreting results of genetic asso-
ciation studies.
A recent critical review of several genes and polymor-
phisms tested as part of commercially available genomic
profiles highlights the challenges of genetic association
testing [51]. The authors used individual gene-disease
association studies as well as meta-analyses to examine
polymorphisms in 56 genes. Of these 32 genes had been
examined in meta-analyses of 160 polymorphism-disease
association comparisons. Only 38% were found to be sta-
tistically significant, with very modest associations. Fur-
thermore, often associations were found with phenotypes
different from the original phenotype being tested for
association. For instance, genes tested in cardiogenomic
profiles were more frequently associated with non-cardiac
diseases. It is anticipated that most disease-phenotype
associations of complex traits are likely to be of modest
significance, with OR <1.5 [52]. Thus, the modest genetic
effects necessitates collaboration, both by performing col-
laborative studies where samples are pooled, as well as by
data-sharing by investigators in order to detect meaning-
ful associations[53].
Non-replication of initial associations can be due to myr-
iad factors including a false-positive result in the first
cohort, population stratification in the first cohort, inade-
quate power in the replication cohort(s), genotyping
errors, selection biases, and true population differences. It
should be noted that lack of an association in the first
cohort often might discourage further studies of that gene
by other investigators, even though the first cohort might
not have had adequate power to truly detect a modest
association. The power to detect associations also depends
on the minor allele frequency, and hence for rare variants
much larger samples would be necessary. It is feasible to
increase the power of genetic studies by using large num-
bers of appropriate controls, thereby increasing the con-
trol to case ratio. The quality of genetic associations will
be significantly enhanced by increasing sample sizes, and
validating initial discoveries by collaborative studies. Fol-
lowing published guidelines for performing and reporting
genetic association studies will improve the quality of
studies and facilitate the discovery of true causal vari-
ants[54,55]. For instance, providing power calculations,
and if the variant under study has been investigated previ-
Table 3: Non-HLA genetic genes associated with JIA that have 
been independently confirmed.
PTPN22
TNFA
MIF
WISP3
SLC11A1
Table 4: Sample sizes requirements for genetic association studies
MAF 10% 20% 30% 40%
Cases controls Cases controls Cases Controls Cases Controls
OR
2.0 223 446 137 274 113 226 107 214
1.5 703 1406 415 830 332 664 304 608
1.3 1751 3502 1016 2032 798 1596 719 1438
Table shows number of cases and controls that need to be typed to detect associations at a significance value of 0.05, power of 80%, for various 
minor allele frequencies, and odds ratios. A case: control ratio of 1:2 is assumed. OR: odds ratio; MAF: minor allele frequency.Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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ously, performance of a meta-analysis would be benefi-
cial. Ultimately, associations that are reproducible, as well
as demonstration of functional consequences of genetic
variation are necessary to translate the results of these
studies to the diagnosis, treatment and understanding of
JIA.
Association studies between JIA and non-HLA variants
have been reviewed previously [33-35]. The following are
some genetic associations that have been confirmed in
more than one cohort. TNFA, the gene encoding the pro-
inflammatory cytokine TNF-α has been the focus of sev-
eral association studies of autoimmune diseases. Associa-
tions between TNFA and different JIA subtypes have been
previously reported. An association between early onset
oligoarticular JIA and TNF variants were reported by
Epplen et al[56]. Another study found associations
between persistent oligoarticular JIA and TNFA  vari-
ants[57]. An association between a SNP at position -857
of  TNFA  and sJIA was reported by Date et al[45].
Schmeling et al found an association between TNFA vari-
ants and psoriatic arthritis polyarticular JIA subtypes[58].
In a case control study of children with JIA, Miterski et al
found no associations with TNFA  SNPs, but found an
association with a microsatellite in the TNFA gene[59].
Thus, while variants in TNFA appear to be associated with
JIA, there are clearly differences between various studies
with regard to the associated variant(s) and/or associated
subtype. It should be noted that some of the associations
could be due to LD, as the TNFA and HLA loci are both
contained in the MHC region.
The gene encoding macrophage migration inhibitory fac-
tor (MIF) has also been investigated in several cohorts of
patients with JIA. A functional SNP at position -173 has
been associated with JIA in the study by Donn et al, in 526
British children with JIA and 259 ethnicity-matched con-
trols[60]. This finding was replicated using an independ-
ent cohort of JIA trios, using TDT [61]. However, this SNP
did not show an association in the studies by Miterski et
al, and Berdeli et al, although it should be noted that both
of these cohorts had smaller number of subjects [59,62].
Of interest, the latter study did find that carriage of -173C
allele was a strong predictor of poor outcome of JIA[62].
It has previously been shown that this allele is a predictor
of poor outcome in sJIA [63]. A recent study of patients
with oligoarticular JIA that had been followed for at least
5 years confirmed that -173C was a predictor of poor
response to intra-articular corticosteroid treatment [64].
Together, these studies imply that MIF variants may be
associated with susceptibility to JIA, as well as the pheno-
type of JIA but should be noted that MIF-173C was not
associated with adult RA in a replication study[65].
The SLC11A1 gene (formerly called NRAMP1) is impor-
tant in natural resistance to various intracellular infections
mediated by macrophages. Variants in this gene have also
been found to be associated with JIA in at least two
cohorts [66,67]. In the first study of Latvian and Russian
children with JIA, a functional promoter microsatellite
polymorphism (allele 3) was found to be associated with
susceptibility to JIA (OR 2.26)[66]. Conversely, another
variant, allele 2, was associated with protection from JIA.
Interestingly, these alleles demonstrate opposite associa-
tions in infection and autoimmunity, with allele 3 confer-
ring susceptibility to autoimmunity and protection from
tuberculosis. Conversely, allele 2 confers protection from
autoimmunity while increasing susceptibility to tubercu-
losis. These suggest that balancing natural selection might
be acting upon this locus. In a subsequent study, Runsta-
dler et al studied both of these SLC11A1 alleles as well as
three SNPs and an insertion/deletion polymorphism in
the region [67]. A six-marker haplotype demonstrated a
strong association with JIA as a group, as well as in oli-
goarticular and polyarticular subtypes. Haplotypes that
did not contain allele 3 identified in the study by Sanjeevi
et al, were also found to show significant association sug-
gesting that variants in this region might have independ-
ent associations with JIA. These two studies support a role
for SLC11A1 variants in JIA susceptibility.
The gene encoding IL-1α, a potent pro-inflammatory
cytokine, has been investigated in several JIA cohorts for a
genetic association. Originally an association was
described between a SNP in the promoter region of IL1A
in Norwegian children with JIA[68]. The association was
most pronounced in those with early onset oligoarticular
JIA. However this finding was not replicated in two
cohorts from the UK in subsequent studies, although one
study investigating a number of polymorphisms demon-
strated an association that was not significant when cor-
rected for multiple comparisons [69,70]. A recent two-
staged association study identified several variants in the
IL-1 gene cluster, and some in the IL-1 receptor cluster
were associated with systemic JIA [71]. IL-6 is another
potently pro-inflammatory cytokine shown to be elevated
in children with JIA[16,72-74]. A functional SNP in the
promoter of the IL6 gene was shown to be associated with
sJIA by Fishman et al. The effect was pronounced in chil-
dren under 5 years of age[75]. This finding was not repli-
cated in a smaller sJIA cohort by Donn et al[69]. However,
using an international cohort of families of children with
sJIA, Ogilvie et al did find a significant association
between the IL6-174 SNP and sJIA, but in children with
onset >5 years[76]. An association between a promoter
variant in IRF1, the gene encoding interferon regulatory
factor and JIA was reported by Donn et al in a cohort of
417 cases with JIA and 276 controls[69]. However, when
they repeated the study using different controls and addi-Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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tional cases, no significant differences in allele or geno-
type frequencies of several IRF1 variants were observed.
Together, these studies illustrate the difficulties of replicat-
ing significant positive findings from initial cohorts in
subsequent larger replication studies.
An association between a SNP (G84A) in the gene encod-
ing the Wnt-1 inducible signaling pathway protein 3
(WISP3) and polyarticular JIA was described by Lamb et
al[77]. After observing a positive association in the initial
cohort of 159 cases and 263 controls, the finding was rep-
licated in an independent cohort of 181 cases and 355
controls. In addition they used parent-child trios for TDT,
which demonstrated a trend towards over-transmission of
the 84A allele. This finding has not been replicated in
other cohorts to our knowledge.
JIA and RA are examples of autoimmune diseases medi-
ated by Th1-immune responses. Synovial T-cells express
high levels of the Th1-chemokine receptor (CCR5). A 32
basepair deletion in the open reading frame of the gene
encoding CCR5 (Δ32) has been shown to be protective
against RA in a meta-analysis of RA association stud-
ies[78]. We have shown that a variant in the promoter
region of CCR5, C-1835T is significantly under-transmit-
ted to children with early onset JIA, and with oligoarticu-
lar JIA[79]. CCR5-Δ32 was also tested in ~700 simplex and
multiplex JIA families and found to be under-transmitted
to children with early onset JIA. These two variants did not
appear to be in LD, and the haplotype that did not contain
either of the "protective" variants was significantly over-
transmitted. In a study of Norwegian adults with RA and
children with JIA, Lindner et al tested CCR5-Δ32, and
failed to replicate these results[80]. When they repeated
the meta-analysis of RA association studies including their
results, the negative association between RA and CCR5-
Δ32 was less pronounced, but still statistically significant
(OR 0.8, p < 0.007). When they compared children with
JIA and the controls, although there was a trend towards a
negative association, it was not statistically significant
(OR 0.82, p < 0.15). The authors in that study did not
investigate other CCR5 variants, including C-1835T.
The gene PTPN22  encodes a lymphoid tyrosine phos-
phatase (LYP) involved in inhibition of T-cell activation.
A SNP within the PTPN22 gene (C1858T) has been shown
to be associated with multiple autoimmune phenotypes
including RA, T1DM, and SLE[65,81-83]. To date, there
have been four studies of this polymorphism in JIA
cohorts [84-86]. The study by Seldin et al did not find an
association between 230 Finnish probands with JIA and
this PTPN22 variant[85]. In contrast, Viken et al reported
an association between JIA and PTPN22 C1858T using
320 Norwegian cases[86]. Another study by Hinks et al
also confirmed an association between PTPN22 and JIA
using 661 JIA cases from the UK[84]. A fourth study using
Czech JIA patients also confirmed the association between
the C1858T variant and JIA[87]. A pooled analysis of
these four studies confirms that carriage of the T allele
increases the susceptibility to JIA, although the magnitude
of the association is only modest, with an OR of ~1.3.
Thus, PTPN22  has been shown to have an association
with JIA.
Strategies to select candidate genes
Selection of candidate genes to be tested for association
with JIA might be aided by careful definition of the phe-
notype, and by testing variants predisposing to mono-
genic diseases that share phenotypic features with JIA
subtypes. For instance, macrophage activation syndrome
(MAS), a potentially life-threatening complication, can
occur in children with sJIA [88]. MAS is characterized by
an overwhelming inflammatory reaction, and is pheno-
typically similar to hemophagocytic lymphohistiocytosis
(HLH). Both familial and acquired forms of HLH are
observed. Four autosomal recessive forms of familial HLH
have been described, and three of these have been linked
to mutations in the genes encoding perforin (PRF1),
Munc13-14 (UNC13D), and syntaxin 11 (STX11)[89].
The products encoded by these genes are involved in con-
trolling granule exocytosis in cytotoxic lymphocytes,
which are necessary for the physiologic termination of cer-
tain immune responses.
Investigations of natural killer (NK) and cytotoxic func-
tions in children with sJIA and MAS have revealed evi-
dence of decreased NK cell activity similar to that seen in
familial HLH [90]. In an investigation of NK cell dysfunc-
tion, children with sJIA demonstrated significantly
decreased NK cell activity compared to pediatric controls,
while decreased NK cell activity was rare in children with
other JIA subtypes[91]. Grom et al, described three chil-
dren with sJIA and MAS who demonstrated low levels of
perforin expression in all cytotoxic cell populations indis-
tinguishable from that in carriers of perforin-deficient
familial HLH[90]. These children did not have PRF1
mutations. In a larger study, 62 children with sJIA (some
with MAS) were screened for PRF1 mutations[92]. Four
mutations were identified, out of which, one (Ala91Val)
was significantly higher in children who had MAS and
sJIA. In a recent study, Zhang et al investigated whether
variants in UNC13D  contribute to MAS in 18 subjects
with MAS and sJIA[93]. None of the 18 had mutations in
PRF1. Two had mutations consistent with a diagnosis of
familial HLH. Nine of the remaining 16 had a unique
haplotype of 12 SNPs, which was significantly greater
than that in controls, (57% vs. 12 %, P < 0.000001), sug-
gesting that this UNC13D haplotype is associated with
MAS. The frequency of this haplotype in 73 children withPediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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sJIA who did not have MAS was not significantly different
compared to controls.
Recently, Hazen et al reported on an 8 year old girl with
sJIA without clinical evidence of MAS, who carried com-
pound heterozygote mutations in the UNC13D gene, and
reduced NK cell cytotoxic function[89]. This suggests that
some children with sJIA without clinical evidence of MAS
have abnormal NK cell function. To estimate the fre-
quency of occult MAS, Behrens et al studied 15 children
with sJIA that underwent bone marrow aspirations [94].
Occult MAS was found in 8 subjects, although only 2 had
clinical evidence of MAS, suggesting that the immune dys-
regulation seen in MAS might be integral to the pathogen-
esis of sJIA. Thus, MAS/HLH could be a part of the
spectrum of sJIA, and therefore, it is plausible that genetic
variants predisposing to familial HLH might also play a
role in susceptibility to MAS, and/or sJIA. Recently, vari-
ants in PRF1, GZMB, UNC13D and Rab27a genes were
tested for association with sJIA using 133 cases and 384
controls [95]. None of the variants demonstrated an asso-
ciation with sJIA. Together, these illustrate that careful
genotype-phenotype correlations, and extending associa-
tions from related phenotypes, will improve the odds of
detecting variants predisposing to susceptibility to JIA and
its subtypes.
Genome-wide studies
Another approach to finding genes underlying complex
traits is to search the entire genome to find genetic mark-
ers that are present more often in affected individuals.
Large extended multiplex pedigrees are relatively rare pre-
cluding conventional parametric linkage studies, in which
parameters such as genetic model, mode of inheritance,
penetrance of each genotype etc need to be specified.
These parameters are often not available for many com-
plex diseases. An alternative approach is to use non-para-
metric methods of linkage such as allele-sharing methods
in affected sibling pairs. Thompson et al performed a
genome wide linkage study using ~400 microsatellite pol-
ymorphisms in 121 JIA affected sibling pair families [96].
Although this study confirmed the role of HLA and iden-
tified several other regions of interest, the study had lim-
ited power and a replication cohort was not available. The
heterogeneity of JIA further results in lower power when
subjects are stratified by different JIA subtypes. The strong-
est evidence of linkage to JIA was near the HLA-DRB1
locus. When subjects were stratified by JIA subtype evi-
dence for linkage was found at different chromosomal
locations for early onset oligoarticular JIA and polyarticu-
lar JIA. This suggests that while some loci such as HLA
contribute to JIA susceptibility in general, there are likely
other loci that influence the different JIA subtypes. This
familiar linkage approach is now being superseded by
association studies that involve the entire genome.
An attractive alternative approach to linkage studies is to
perform a genome-wide association study (GWAS), which
does not require multiplex families, but can be performed
with large number of cases and controls. A GWAS exam-
ines tens of thousands of genetic variants in a large
number of unrelated cases and controls. GWAS have led
to the successful identification of several genetic variants
that underlie complex autoimmune phenotypes includ-
ing T1DM, RA, IBD, AS [97-101]. A large collaborative
GWAS utilized 3000 shared controls and 2000 cases of 7
different common complex traits which included IBD, RA
and T1DM[99]. In all, 17000 individuals were genotyped
for >500,000 SNPs. This study confirmed previously
reported associations such as IL23R, and NOD2 for IBD,
HLA-DRB1 and PTPN22 for RA and T1DM as well as sev-
eral other loci for T1DM[99]. In addition this study iden-
tified several new loci that showed strong evidence of
association with IBD, RA and T1DM. Some SNPs appear
to be associated with more than one autoimmune disease.
Other investigators have used GWAS to identify other loci
underlying RA such as TRAF1/C5[102]. Interestingly
another group using a candidate gene approach also
reported an association between RA and TRAF1/C5 locus
[103]. GWAS have also been successful in identifying
other RA associated loci. Two groups reported associa-
tions between individuals with RA and variants located on
6q23, near which are some possible candidate
genes[102,104]. Together these studies demonstrate the
feasibility of performing GWAS to identify genes underly-
ing predisposition to well defined phenotypes.
To date there are no published studies of GWAS in JIA
cohorts although several groups are undertaking such
studies. Several GWAS studies are in progress in JIA using
high density SNP platforms. Data published in abstract
forms suggest that this approach might be successful in
identifying JIA associated variants. In a GWAS utilizing
individuals with JIA and RA using a SNP platform with
115,075 SNPs, John et al were able to detect known sus-
ceptibility loci such as PTPN22 and HLA [105]. Using a
high density SNP GWAS, Thompson et al were able to
identify specific polymorphisms potentially involved in
JIA at large, as well as other SNPs that appear to influence
specific JIA subtypes [106]. Confirmation of initial discov-
eries from these studies in in independent cohorts is nec-
essary. The consolidation of available cohorts is an active
need to improve power, as well as to enable replication
studies.
Genetic variables underlying autoimmunity in 
general
It has increasingly become clear that autoimmune dis-
eases can cluster both in individuals, as well as in fami-
lies[107]. We have shown previously, using a case-control
design that relatives of patients with JIA have increasedPediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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prevalence of several autoimmune diseases, especially
autoimmune thyroid disease [26]. Others have found
increased prevalence of autoimmune thyroid disease or
celiac disease in patients with JIA [108-110]. Prevalence of
T1DM is also increased in children with JIA[23,111].
Together these studies suggest that clinically distinct
autoimmune phenotypes cluster in individuals and fami-
lies. This supports the hypothesis that common genetic
factors might predispose to clinically distinct autoim-
mune phenotypes.
There are now several concrete examples of genetic vari-
ants that influence susceptibility to multiple clinically dis-
tinct autoimmune disorders. For instance, a SNP in the
CTLA4 gene, CT60, has been found to be associated with
autoimmune thyroiditis, and T1DM[112]. The same vari-
ant has been found to be associated with RA in a meta-
analyses [65]. However, this SNP does not appear to play
a major role in susceptibility to RF-negative RA or
JIA[65,113]. A PTPN22 variant has also been associated
with multiple autoimmune diseases including RA, SLE,
T1DM and JIA. Similarly there are other genetic variants
that are associated with multiple autoimmune diseases
(Table 5). For instance variants in TNFA appear to be asso-
ciated with RA, JIA, and SLE. Variants in CCR5 appear to
be protective against both RA and JIA [78,79,114]. Simi-
larly, IL23R variants seems to be associated with IBD, Pso-
riasis and AS, but not with RA [97,101,115-117].
Together, these examples suggest that genetic variants
which underlie susceptibility to other autoimmune phe-
notypes could also potentially be involved in JIA suscepti-
bility. This hypothesis was tested by Thomson et al, who
tested IL2RA variants associated with both RA and T1DM
in children with JIA[118]. IL2RA variants were also associ-
ated with JIA. These results suggest that investigating
genetic variants demonstrating association with multiple
autoimmune phenotypes in JIA cohorts might be an
attractive approach to find JIA susceptibility genes.
In summary, JIA appears to be influenced by genetic fac-
tors, both within and outside the HLA region. While many
of the HLA associations have been replicated in independ-
ent cohorts, only a few of the non-HLA associations have
been replicated. The major reason for non-replication
appears to be insufficient power. Advances such as
genome-wide association studies and collaborative efforts
are likely to result in the discovery of new genetic associa-
tions, as well as validate (or refute) some of the previously
described associations. Finally understanding how a
genetic variant associated with JIA and/or other autoim-
mune diseases influences disease susceptibility is essential
to translating findings from the lab to the care of children
with JIA.
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Table 5: Examples of genes associated with multiple autoimmune diseases:
Gene Autoimmune diseases associated
CTLA4 RA, AITD, SLE, T1DM, MS, Celiac disease, autoimmune hepatitis
PTPN22 RA, SLE, T1DM, JIA, Vitiligo, Wegener's, AITD
PDCD1 SLE, RA, T1DM
TNFA RA, JIA, Crohn's disease
SLC11A1 Crohn's, JIA, RA, T1DM
IL-6 JIA, T1DM, SLE
IL-1A JIA, RA
MIF Alopecia areata, JIA, RA, Ulcerative colitis
STAT4 RA, SLE
IL-2RA T1DM, RA, JIA
CCR5 JIA, RA, MS, T1DM
IL23R Crohn's disease, Psoriasis, spondyloarthropathy
RA: Rheumatoid arthritis, AITD: autoimmune thyroid disease, SLE: systemic lupus erythematosus, T1DM: type 1 diabetes mellitus, MS: multiple 
sclerosis, JIA: juvenile idiopathic arthritis,.Pediatric Rheumatology 2008, 6:11 http://www.ped-rheum.com/content/6/1/11
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